Elicio Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Boston, MA
ELTX chart
What traders are saying about $ELTX
Latest postsElicio Therapeutics, Inc. news
- Elicio Therapeutics activates Phase 1 study for pancreatic cancer
scanx.trade ·
- Elicio Therapeutics, Inc. Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026 And Announces Simultaneous Publication In Nature Medicine
marketscreener.com ·
- Elicio Therapeutics, Inc. Estimates – NASDAQ:ELTX
TradingView ·
- Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Yahoo Finance ·
- ELTX Stock Price, Quote & Chart
ChartMill ·
- Vaccine Targeting KRAS in Pancreatic Cancer Shows Promise
Memorial Sloan Kettering Cancer Center ·
- Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Yahoo Finance ·
- Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance ·
- Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Yahoo Finance ·
- Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Yahoo Finance ·
- Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
stocktwits.com ·
Elicio Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $2.3M |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M |
| Diluted EPS | $-2.58 | $-4.25 | $-6.96 | $-89.27 |
| Total assets (year end) | $25.9M | $28.2M | $27.1M | $22.7M |
| Cash and equivalents (year end) | $18.6M | $17.6M | $12.9M | $6.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Elicio Therapeutics, Inc.
- Ticker
- ELTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1601485
- Former names
- Angion Biomedica Corp.
Frequently asked questions
What exchange is Elicio Therapeutics, Inc. listed on?
Elicio Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ELTX.
What industry is Elicio Therapeutics, Inc. in?
Elicio Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Elicio Therapeutics, Inc. headquartered?
Elicio Therapeutics, Inc.'s business address on file with the SEC is in Boston, MA.
When does Elicio Therapeutics, Inc.'s fiscal year end?
Elicio Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Elicio Therapeutics, Inc. report?
Elicio Therapeutics, Inc. reported $2.3M in revenue for calendar year 2022, according to its SEC filings.